ResMed (RMD) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
ResMed (RMD) share price 'may have overcompensated' - Morgan Stanley
October 27, 2023 11:38 AM EDTMorgan Stanley upgraded shares of ResMed (NYSE: RMD) to Overweight from Equal-Weight, lowering the price target on the stock to $169 from $180 per share in a note to clients Friday.
Analyst Sean Laaman told investors that their deep dive analysis on the obstructive sleep apnea (OSA) market suggests the... More
